# Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

> **NCT00956930** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 45 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **RADIATION:** yttrium Y 90 glass microspheres
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00956930
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2016-06-02
- **Final completion:** 2016-07-15
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00956930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00956930, "Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00956930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*